US-based genomics services provider Wuxi NextCode has raised $75m in a series B round featuring Amgen Ventures, the corporate venturing arm of biopharmaceutical company Amgen.
The round was co-led by Singapore government-owned investment firm Temasek and private equity firm Yunfeng Capital, and also featured private equity firm 3W Partners.
Wuxi NextCode operates a contract genomics platform that offers features such as sequencing, secondary analysis, storage, interpretation and scalable analytics.
The company was founded as NextCode Health in 2013 but was rebranded two years later when China-headquartered open-access pharmaceutical platform provider Wuxi AppTec purchased a majority stake.
Polaris Partners and Arch Venture Partners had supplied $15m in series A funding for NextCode in 2013.
Hannes Smarason, chief executive of WuXi NextCode, said: “We are building the world’s leading genomic data platform, applying genome sequencing data at scale to improve human health and wellness around the world.
“Our rapidly expanding business is serving the world’s leading precision medicine initiatives as well as genome-driven diagnostics and wellness enterprises worldwide.”
– A version of this article originally appeared on our sister site, Global Government Venturing